
This guide helps leaders compare legacy, cloud-based, and cloud-native PACS models5 so they can choose the right fit for their goals and position their practices for long-term success.
Today's imaging centers face new demands:1 AI integration, remote collaboration, seamless scalability, 2 and higher patient expectations for better turn-around times. Meeting these requires technology that drives both clinical accuracy and operational efficiency.
PACS3 remains central to this mission, ensuring fast, reliable access to images that support timely diagnoses and confident care decisions.


![(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/mei.XUQJWkpAJI.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)

![(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/mei.XUQJWkpAJI.jpg?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)



![(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/mei.XUQJWkpAJI.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)



![RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/screenshot-2026-05-27-205827.278Ys6PYU3.png?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)



